



EMVision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

ASX Release

AGM CHAIRMAN'S ADDRESS

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company") is pleased to provide the following Chairman's address and separately released CEO Presentation to be made at the Company's 2023 Annual General Meeting at 2.00pm AEST today.

Chairman's Address

Welcome to EMVision's 2023 Annual General Meeting.

The Company has made outstanding progress in the past year, and I am pleased to report we are on course to deliver the world's first truly portable Point-of-Care imaging devices capable of opening the door to significantly improved outcomes for stroke patients and their families.

This year has seen our Company generate strong momentum from multi-site clinical trials of EMVision's portable first-generation brain scanner. As at today, we have production equivalent portable brain scanners being trialled in three Australian hospitals in major cities and are targeting market entry in FY25.

The pre-validation and validation phases of our trials support our product and clinical development along with the market clearance process for our major commercial markets. The enthusiasm and commitment of the clinical research teams at each of our three trial sites has been exceptional. This is reflected in both the rate at which they have been able to recruit patients into our trial and supports the positive impact that they can see our product having for stroke patients in the future.

We have achieved positive interim test results and were able to share encouraging early case studies and insights at the Stroke Society of Australasia in August and at the World Stroke Congress in October. These were subsequently published in the International Journal of Stroke. This evidence building and awareness generating effort ties in nicely with our upcoming showcase, with our partner Keysight Technologies, at the Radiological Society of North America (RSNA) meeting later this month. For many of the international medical imaging community, RSNA will represent the first time they will be exposed to EMVision and our devices. It provides us with a unique opportunity to engage with the international clinical community, future prospective customers, and continue discussions with potential go-to-market partners.

Going forward, as we process further data from our trials, we will target further engagement at premier international stroke conferences to support our podium strategy and seek to expand our network of supportive international key opinion leaders in stroke care.

Looking to 2024, it will also be a big year for our second generation, first responder device. Our advanced prototype of our ultra-lightweight helmet scanner is undergoing bench testing at present as we progress towards delivery of a proof-of-concept unit. This unit will undergo road and air ambulance trials with our collaborators at the Australian Stroke Alliance and represents a major milestone of the "golden hour" program. The tyranny of distance, whilst a major challenge to equitable healthcare delivery nationwide, is not unique to Australia. This is a global challenge and one we believe our portable, lightweight and cost-effective brain imaging technology can go a long way to addressing and thereby relieving the global societal and health economic burden of stroke and other medical emergencies that require urgent brain imaging and care.

Throughout the year we have been a recipient of an additional \$6m in non-dilutive grant funding. We are grateful for the support of these programs and have an R&D rebate due this quarter. We are well capitalised for our trials and are proactively engaging in further domestic and international non-dilutive grant funding opportunities to accelerate and support our path to market.

Building on the strong foundation established by Ron Weinberger, Scott Kirkland took over as EMVision's CEO and MD earlier this year as we advance from a technology driven organisation to a product commercialisation and customer focused Company. Thank you, Scott and Ron for your outstanding and ongoing contributions.

I'd like to take this opportunity to thank the enthusiastic and talented EMVision team in Sydney and Brisbane who have worked successfully to deliver our innovative product platform and our clinical trials that de-risk our journey and drive shareholder value.

I would also like to acknowledge our clinical collaborators in the hospitals and thank the patients and their families who have participated in our trials. Ultimately it is future stroke patients whose lives we are aspiring to improve.

Thank you to my fellow Directors for their dedication and hard work during the year and finally to our fellow shareholders, thank you all for your support of EMVision. We look forward to keeping you updated on our progress during another exciting year ahead.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 800
andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
CEO and Managing Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited (ASX:EMV) is an innovative Australian medical device company developing a novel approach to looking inside the human body. Our product pipeline includes portable, non-invasive, affordable and safe neuroimaging devices.

Our vision is to help transform and improve the timely diagnosis and treatment of stroke and other time sensitive medical emergencies, at the point-of-care.

EMVision has offices in Sydney and Brisbane www.emvisionmedical.com

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and

could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Inherent risks of Investment in Medical Device development Companies

There are a number of inherent risks associated with the development of new medical device products to a marketable stage. The clinical trial process, which is often lengthy, is designed to assess the safety and efficacy of a device prior to commercialisation and there is no guarantee of achieving the outcomes necessary to generate a viable commercial product. Other risks include uncertainty of patent protection and proprietary rights, the obtaining of necessary regulatory authority approvals and the evolving competitive landscape. Companies such as EMVision are dependent on the success of their research and development projects, product development and on the ability to attract funding to support these activities. Investment in research and development and novel product development cannot be assessed on the same fundamentals as trading and manufacturing enterprises. Therefore investment in Companies specialising in such development must be regarded as speculative. EMVision recommends that professional investment advice be sought prior to such investments and cautions investors that the risks of an investment in an entity such as EMVision is not limited to the risks disclosed in this announcement.